Clinical Trials Browser

Phase 2 × Afatinib × 1 year × Clear all

NCT06385483 2026-03-19

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Phase 2 Active not recruiting

19 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Phase 2 Completed

50 enrolled 14 charts

Squamous Cell Cancers of the Head and Neck

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT04497584 2025-10-01

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Phase 2 Active not recruiting

Advanced Squamous Non Small Cell Lung Cancer

NCT05588609 2025-09-18

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

Head and Neck Neoplasms

NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

Phase 2 Terminated

32 enrolled 14 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms